The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study

REFERENCES

1. 1.↵
   1. Lee SH,
   2. Lee EJ,
   3. Chung SW,
   4. Song R,
   5. Moon JY,
   6. Lee SH,
   7. et al.

   Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 2013;33:1689–92.

   OpenUrl
2. 2.↵
   1. Jakobsen AK,
   2. Jacobsson LT,
   3. Patschan O,
   4. Askling J,
   5. Kristensen LE

   . Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS One 2014;9: e113602.

   OpenUrl
3. 3.↵
   1. El Maghraoui A

   . Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 2011;22:554–60.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Lehtinen K

   . Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174–6.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Levy AR,
   2. Szabo SM,
   3. Rao SR,
   4. Cifaldi M,
   5. Maksymowych WP

   . Estimating the occurrence of renal complications among persons with ankylosing spondylitis. Arthritis Care Res 2014;66:440–5.

   OpenUrl
6. 6.↵
   1. Ben Taarit C,
   2. Ajlani H,
   3. Ben Moussa F,
   4. Ben Abdallah T,
   5. Ben Maïz H,
   6. Khedher A

   . [Renal involvement in ankylosing spondylitis: concerning 210 cases]. [Article in French] Rev Med Interne 2005;26:966–9.

   OpenUrlPubMed
7. 7.↵
   1. Samia B,
   2. Hazgui F,
   3. Abdelghani KB,
   4. Hamida FB,
   5. Goucha R,
   6. Hedri H,
   7. et al.

   [Renal abnormalities in ankylosing spondylitis]. [Article in French] Nephrol Ther 2012;8:220–5.

   OpenUrlPubMed
8. 8.↵
   1. Singh G,
   2. Kumari N,
   3. Aggarwal A,
   4. Krishnani N,
   5. Misra R

   . Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 2007;34:371–3.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Kobak S,
   2. Oksel F,
   3. Kabasakal Y,
   4. Doganavsargil E

   . Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 2007;26:2191–4.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Haroon NN,
    2. Paterson JM,
    3. Li P,
    4. Inman RD,
    5. Haroon N

    . Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 2015;163:409–16.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Moltó A,
    2. Etcheto A,
    3. van der Heijde D,
    4. Landewé R,
    5. van den Bosch F,
    6. Bautista Molano W,
    7. et al.

    Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016;75:1016–23.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection;
    2. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

    . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.

    OpenUrlFREE Full Text
13. 13.↵
    1. EuroQol Group

    . EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Dougados M,
    2. Simon P,
    3. Braun J,
    4. Burgos-Vargas R,
    5. Maksymowych WP,
    6. Sieper J,
    7. et al.

    ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249–51.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Levey AS,
    2. Coresh J,
    3. Balk E,
    4. Kausz AT,
    5. Levin A,
    6. Steffes MW,
    7. et al;
    8. National Kidney Foundation

    . National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Lee K,
    2. Koval JJ

    . Determination of the best significance level in forward logistic regression. Commun Stat Simul Comput 1997;26:559–75.

    OpenUrl
17. 17.↵
    1. Shtatland ES,
    2. Cain E,
    3. Barton MB

    . The perils of stepwise logistic regression and how to escape them using information criteria, and the Output Delivery System, SUGI’26 Proceedings, Paper 222–26. Cary: SAS Institute Inc.
18. 18.↵
    1. Hosmer DW,
    2. Lemeshow S

    . Applied logistic regression. New York: John Wiley and Sons Inc.; 1989.
19. 19.↵
    1. Steyerberg EW,
    2. Eijkemans MJ,
    3. Harrell FE Jr,
    4. Habbema JD

    . Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000;19:1059–79.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Rodrigues CE,
    2. Vieira WP,
    3. Bortoluzzo AB,
    4. Gonçalves CR,
    5. da Silva JA,
    6. Ximenes AC,
    7. et al.

    Low prevalence of renal, cardiac, pulmonary, and neurological extra-articular clinical manifestations in spondyloarthritis: analysis of the Brazilian Registry of Spondyloarthritis. Rev Bras Reumatol 2012;52:375–83.

    OpenUrlPubMed
21. 21.↵
    1. Azevedo DC,
    2. Ferreira GA,
    3. Carvalho MA

    . IgA nephropathy in patients with spondyloarthritis followed-up at the Rheumatology Service of Hospital das Clínicas/UFMG. Rev Bras Reumatol 2011;51:417–22.

    OpenUrlPubMed
22. 22.↵
    1. Zhang W,
    2. He J,
    3. Zhang F,
    4. Huang C,
    5. Wu Y,
    6. Han Y,
    7. et al.

    Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 2013;26:243–53.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Chronic Kidney Disease Prognosis Consortium,
    2. Matsushita K,
    3. van der Velde M,
    4. Astor BC,
    5. Woodward M,
    6. Levey AS,
    7. et al.

    Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–81.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Bodnár N,
    2. Kerekes G,
    3. Seres I,
    4. Paragh G,
    5. Kappelmayer J,
    6. Némethné ZG,
    7. et al.

    Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011;38:723–9.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Mathieu S,
    2. Joly H,
    3. Baron G,
    4. Tournadre A,
    5. Dubost JJ,
    6. Ristori JM,
    7. et al.

    Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47:1203–7.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Papagoras C,
    2. Voulgari PV,
    3. Drosos AA

    . Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013;31:612–20.

    OpenUrlPubMed
27. 27.↵
    1. Peters MJ,
    2. van Eijk IC,
    3. Smulders YM,
    4. Serne E,
    5. Dijkmans BA,
    6. van der Horst-Bruinsma IE,
    7. et al.

    Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37:161–6.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. van Eijk IC,
    2. Peters MJ,
    3. Serné EH,
    4. van der Horst-Bruinsma IE,
    5. Dijkmans BA,
    6. Smulders YM,
    7. et al.

    Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009;68:362–6.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Szabo SM,
    2. Levy AR,
    3. Rao SR,
    4. Kirbach SE,
    5. Lacaille D,
    6. Cifaldi M,
    7. et al.

    Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294–304.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Peters MJ,
    2. Visman I,
    3. Nielen MM,
    4. Van Dillen N,
    5. Verheij RA,
    6. van der Horst-Bruinsma IE,
    7. et al.

    Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579–81.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Huang YP,
    2. Wang YH,
    3. Pan SL

    . Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis – a population-based longitudinal follow-up study. PLoS One 2013;8:e64155.

    OpenUrlCrossRefPubMed